This article is more than 5 years old. Information may no longer be current.
Oculis initiates OCS-01 trial for inflammation, pain after cataract surgery
Click Here to Manage Email Alerts
The first patient has been dosed in a phase 2b clinical trial of OCS-01 for the treatment of inflammation and pain after cataract surgery, Oculis announced in a press release.
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone based on Oculis’ solubilizing nanoparticle (SNP) technology platform. The prospective, multicenter, randomized phase 2b clinical trial is evaluating safety and efficacy.
“Our SNP platform enables us to formulate topical therapeutics for delivery to both the back and front of the eye,” Riad Sherif, MD, CEO of Oculis, said in the release. “This study initiates the clinical evaluation of OCS-01 in a second indication, which is its first for the front of the eye. Our lead program is in a phase 2b trial of OCS-01 in patients with DME. That study has completed enrollment, and we anticipate presenting the study results early in 2020.”
The formulation would be the first once-daily topical steroid to treat inflammation and pain after ocular surgery, the release said.